-
Is the recent BMS-Nektar NKTR-214 deal really the most lucrative agreement in biotech history?
Bristol-Myers Squibb (BMS) and Nektar Therapeutics (Nektar) have agreed to a Global Development & Commercialisation Collaboration, to work on Nektar’s lead oncology program, the CD122-biased agonist, NKTR-214. We assess who we think got the best out of this deal!
-
Patent Attorneys in Brisbane
Providing Patent Attorney services in Brisbane Innofy have award-winning Patent Attorneys headquartered…
-
Diagnostics Inventions in the US: The Situation Worsens…
On 4 August 2017, the United States District Court handed down another…
-
The Australian TGA wants to hear from stakeholders
The Australian Therapeutic Goods Administration (TGA) is reaching out! Please take 10-15…
-
Opportunity – FDA encouraging manufacture and distribution of new generic drugs
The U.S. Food and Drug Administration (FDA) are desperately seeking to increase competition for prescription drugs. A recent blog post by the FDA Commissioner has outlined their strategy for reducing the barriers to generic drug approval.
-
TbALPH1 identified as hot target for African Sleeping Sickness
New treatments for African trypanosomiasis (aka African Sleeping Sickness) have been a hot topic for university research and not for profit organisations for over a decade. Researchers at JMU (Germany) have discovered the latest hot hit.
Posts tagged with ‘biotech’
Innofy Intellectual Property > biotech